By acting on a family of four GPCRs (i.e., EP1–4) and more specifically on EP1 and EP4, PGE2 promotes multiple cellular events including the inactivation of host antitumor immune cells, the enhancement of cancer cell migration and invasiveness, tumor-associated angiogenesis and lymphangiogenesis. The gene discussed is PTGER1; the disease is cancer.